Drugs / INV-8989
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07610798 | Jun 2026 → May 2029 expected | biliary tract cancer, colorectal cancer, endometrial cancer, non-small cell lung carcinoma +2 | Shenzhen Ionova Life Sciences Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INV-8989 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07610798 ↗ |